CAS: 7377-26-6; Methyl 4-(Chlorocarbonyl)Benzoate

相似化合物

34040-64-7 1571-08-0 120-61-6

上下游产品

CAS号1679-64-7 对苯二甲酸单甲酯 | CAS号1571-08-0 对甲酰基苯甲酸甲酯 | CAS号42967-55-5 对苯二甲酸一甲酯钾盐 | CAS号120-61-6 对苯二甲酸二甲酯 | CAS号67-56-1 甲醇 | CAS号100-20-9 对苯二甲酰氯 | CAS号17874-79-2 5-甲氧羰基-2-吡啶甲酸 | CAS号100-21-0 对苯二甲酸(PTA) | CAS号108418-22-0 2-(dimethylamin... | CAS号108418-21-9 4-(4-hexylbenzo... | CAS号108783-73-9 4-(5-phenyl-1,3... | CAS号108783-86-4 4-[5-(4-methylp... | CAS号108418-23-1 2-[4-(4-hexylbe... | CAS号108418-18-4 methyl 4-(4-hex... | CAS号108418-19-5 4-(4-hexylbenzo... | CAS号1093395-65-3 Methyl 4-(7-bro... | CAS号108418-26-4 2-[4-(4-hexylbe... | CAS号56893-25-5 4-(2-溴乙酰基)苯甲酸甲酯

Methyl Vinyl Terephthalate 反应生成 4-氯甲酰基苯甲酸甲酯
参考文献:Stepanov,F.N.; Veretenova,T.N.,Journal Of Organic Chemistry Ussr (English Translation),1967,Vol. 3,P. 1000-1004
标题:Stepanov,F.N.; Veretenova,T.N.,Journal Of Organic Chemistry Ussr (English Translation),1967,Vol. 3,P. 1000-1004

专利信息

专利号:US-9481678-B2
优先权日:2015-02-09
标题 :Substituted pyrrolo[2,3-D]dipyrimidines for selectively targeting tumor cells with FR-alpha and FR-beta type receptors
发明人：GANGJEE ALEEM; MATHERLY LARRY H
权利人:DUQUESNE UNIV OF THE HOLY GHOST; UNIV WAYNE STATE
摘要:Pyrrolo[2,3-d]pyrimidine derivatives, and pharmaceutical acceptable salts thereof, useful in therapeutically treating patients with cancer are disclosed. These compounds selectively target folate receptors (FR) of cancerous tumor cells and inhibit purine synthesis and hence, DNA synthesis.

专利号:US-9611281-B2
优先权日:2013-12-05
标题:BODIPY derivatives and methods of synthesis and use thereof
发明人：YOU YOUNGJAE; AWUAH SAMUEL; WATLEY RYAN
权利人:UNIV OKLAHOMA
摘要:Derivatives of BODIPY (boron dipyrromethene difluoride) and their synthesis and use are disclosed.

专利号:US-10647688-B2
优先权日:2014-12-19
标题:Compounds, synthesis method thereof and use of same in medicine and in cosmetics
发明人：PORTAL THIBAUD
权利人:GALDERMA RES & DEV
摘要:Novel compounds, synthesis methods and use of the same in medicine and in cosmetics are disclosed. Also disclosed, are novel compounds and ligands that modulate RARs.

专利号:US-4374770-A
优先权日:1981-10-08
标题:Process for preparation of aromatic acid chlorides
发明人：HYATT JOHN A; KASHDAN DAVID S
权利人:EASTMAN KODAK CO
摘要:Disclosed is a process for converting aromatic aldehydes to the corresponding acid chlorides by reacting an aromatic aldehyde with sulfuryl chloride in the presence of a catalytic amount of a phosphine, phosphine oxide or phosphonium compound. The product compounds produced by the process of this invention are useful as chemical synthesis intermediates in the preparation of pharmaceuticals, dyes, herbicides and photographic chemicals.

专利号:WO-9948868-A9
优先权日:1998-03-26
标 题 :Heterocyclic classes of compounds for the modulating tyrosine protein kinase
发明人：FONG ANNIE; HANNAH ALISON; HARRIS G DAVIS; HIRTH PETER; HUBBARD STEVEN R; LANGECKER PETER; LIANG CONGXIN; MCMAHON GERALD; MOHAMMADI MOOSA; SCHLESSINGER JOSEPH; SHAWVER LAURA K; SUN LI; TANG PENG C; ULLRICH AXEL
权利人:SUGEN INC; UNIV NEW YORK; MAX PLANCK INST FUR BIOCHEMIE; FONG ANNIE; HANNAH ALISON; HARRIS G DAVIS; HIRTH PETER; HUBBARD STEVEN R; LANGECKER PETER; LIANG CONGXIN; MCMAHON GERALD; MOHAMMADI MOOSA; SCHLESSINGER JOSEPH; SHAWVER LAURA K; SUN LI; TANG PENG C; ULLRICH AXEL
摘要:The invention relates to certain indolinone-based and pyrazolylamide-based compounds, their method of synthesis, and combinatorial libraries consisting of the compounds. The invention also relates to methods of modulating the function of protein kinases using these compounds and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.

专利号:EP-2084147-B1
优先权日:2006-08-29
标 题:Heterocyclic fxr binding compounds
发明人：KREMOSER CLAUS; DEUSCHLE ULRICH; ABEL ULRICH; SCHULZ ANDREAS
权利人:PHENEX PHARMACEUTICALS AG
摘要:The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists or partial agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.